Journal
Multiple Sclerosis Journal
Publication Date
10-1-2023
Volume
29
Issue
11-12
First Page
1471
Last Page
1481
Document Type
Open Access Publication
DOI
10.1177/13524585231192460
Rights and Permissions
Bar-Or A, Cross AH, Cunningham AL, Hyvert Y, Seitzinger A, Gühring H, Drouin EE, Alexandri N, Tomic D, Montalban X. Antibody response to SARS-CoV-2 vaccines in patients with relapsing multiple sclerosis treated with evobrutinib: A Bruton's tyrosine kinase inhibitor. Mult Scler. 2023 Oct;29(11-12):1471-1481. doi: 10.1177/13524585231192460. Epub 2023 Aug 25.© The Author(s), 2023. Creative Commons License (CC BY-NC 4.0) This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). Request permissions for this article.
Recommended Citation
Bar-Or, Amit; Cross, Anne H; Cunningham, Anthony L; Hyvert, Yann; Seitzinger, Andrea; Gühring, Hans; Drouin, Elise E; Alexandri, Nektaria; Tomic, Davorka; and Montalban, Xavier, "Antibody response to SARS-CoV-2 vaccines in patients with relapsing multiple sclerosis treated with evobrutinib: A Bruton's tyrosine kinase inhibitor." Multiple Sclerosis Journal. 29, 11-12. 1471 - 1481. (2023).
https://digitalcommons.wustl.edu/oa_4/2363
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
